用于糖尿病黄斑水肿的新一代抗 VEGF 药物。
Next-generation anti-VEGF agents for diabetic macular oedema.
机构信息
Private Retina Office, University of Buenos Aires, Buenos Aires, Argentina.
Division of Ophthalmology, Tel Aviv Sourasky Medical Center, affiliated to Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
出版信息
Eye (Lond). 2022 Feb;36(2):273-277. doi: 10.1038/s41433-021-01722-8. Epub 2021 Aug 9.
Abstract
The treatment and outcomes of diabetic macular oedema (DMO) have improved with the introduction of intravitreal injections. However, real-world data reveal that the burden of DMO treatment causes large gaps in outcomes between randomized clinical trials and daily clinical practice. Long-lasting intravitreal drugs and devices for DMO might reduce this disparity by achieving optimal treatment due to more feasible injection regimens. In this manuscript, we cover pharmacodynamics, preliminary results from clinical trials, and safety behavior about brolucizumab, faricimab, conbercept, KSI-301, and port-delivery system WR42221. These treatments might present the first step to control the global epidemic of diabetic eye disease in real life.
摘要
随着玻璃体腔内注射的引入，糖尿病性黄斑水肿（DMO）的治疗和结果得到了改善。然而，真实世界的数据显示，DMO 治疗的负担导致了随机临床试验和日常临床实践之间的结果存在较大差距。长效玻璃体腔内药物和设备可能会通过更可行的注射方案实现最佳治疗，从而减少这种差异。在本文中，我们介绍了 brolucizumab、faricimab、康柏西普、KSI-301 和经端口输送系统 WR42221 的药效学、临床试验的初步结果和安全性行为。这些治疗方法可能是控制现实生活中糖尿病眼病全球流行的第一步。
相似文献
1
Next-generation anti-VEGF agents for diabetic macular oedema.用于糖尿病黄斑水肿的新一代抗 VEGF 药物。
Eye (Lond). 2022 Feb;36(2):273-277. doi: 10.1038/s41433-021-01722-8. Epub 2021 Aug 9.
2
Anti-vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema.抗血管内皮生长因子联合玻璃体内注射类固醇治疗糖尿病性黄斑水肿。
Cochrane Database Syst Rev. 2018 Apr 18;4(4):CD011599. doi: 10.1002/14651858.CD011599.pub2.
3
Efficacy and safety of intravitreal anti-VEGF therapy in diabetic retinopathy: what we have learned and what should we learn further?抗血管内皮生长因子药物玻璃体腔内注射治疗糖尿病视网膜病变的疗效和安全性：我们已经学到了什么，还应该进一步学习什么？
Expert Opin Biol Ther. 2022 Oct;22(10):1275-1291. doi: 10.1080/14712598.2022.2100694. Epub 2022 Jul 17.
4
Faricimab: Transforming the Future of Macular Diseases Treatment - A Comprehensive Review of Clinical Studies.法西单抗：改变黄斑疾病治疗的未来——临床研究的综合评价。
Drug Des Devel Ther. 2023 Sep 18;17:2861-2873. doi: 10.2147/DDDT.S427416. eCollection 2023.
5
Anti-vascular endothelial growth factor for diabetic macular oedema.抗血管内皮生长因子治疗糖尿病性黄斑水肿
Cochrane Database Syst Rev. 2014 Oct 24(10):CD007419. doi: 10.1002/14651858.CD007419.pub4.
6
Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema.采用抗血管内皮生长因子疗法治疗糖尿病性黄斑水肿的抗血管生成治疗
Cochrane Database Syst Rev. 2009 Oct 7(4):CD007419. doi: 10.1002/14651858.CD007419.pub2.
7
Suboptimal outcomes and treatment burden of anti-vascular endothelial growth factor treatment for diabetic macular oedema in phakic patients.有晶状体眼糖尿病黄斑水肿患者接受抗血管内皮生长因子治疗的结局不佳和治疗负担。
Eye (Lond). 2024 Jan;38(1):215-223. doi: 10.1038/s41433-023-02667-w. Epub 2023 Aug 4.
8
Intravitreal Bevacizumab Alone Versus Intravitreal Bevacizumab In Combination With Focal Macular Photocoagulation In Diabetic Macular Oedema.单纯玻璃体腔注射贝伐单抗与玻璃体腔注射贝伐单抗联合黄斑区局部光凝治疗糖尿病性黄斑水肿的对比研究
J Ayub Med Coll Abbottabad. 2022 Jan-Mar;34(1):160-163. doi: 10.55519/JAMC-01-9721.
9
Diabetic retinopathy and diabetic macular oedema pathways and management: UK Consensus Working Group.糖尿病视网膜病变和糖尿病黄斑水肿的诊治途径：英国共识工作组。
Eye (Lond). 2020 Jun;34(Suppl 1):1-51. doi: 10.1038/s41433-020-0961-6.
10
Sodium-glucose co-transporter 2 inhibitor therapy reduces the administration frequency of anti-vascular endothelial growth factor agents in patients with diabetic macular oedema with a history of anti-vascular endothelial growth factor agent use: A cohort study using the Japanese health insurance claims database.钠-葡萄糖共转运蛋白 2 抑制剂治疗可降低有抗血管内皮生长因子药物使用史的糖尿病黄斑水肿患者抗血管内皮生长因子药物的给药频率：使用日本健康保险索赔数据库的队列研究。
Diabetes Obes Metab. 2024 Apr;26(4):1510-1518. doi: 10.1111/dom.15454. Epub 2024 Jan 19.
引用本文的文献
1
Enhancement of retinal Müller glia's phagocytic activity against hard exudates by conbercept activation of PPARγ-CD36 axis in diabetic retinopathy.在糖尿病性视网膜病变中，通过康柏西普激活PPARγ-CD36轴增强视网膜Müller胶质细胞对硬性渗出物的吞噬活性。
Int J Ophthalmol. 2025 Jul 18;18(7):1252-1261. doi: 10.18240/ijo.2025.07.07. eCollection 2025.
2
Efficacy and safety of dexamethasone versus intravitreal aflibercept implants for macular edema: a systematic review and meta-analysis.地塞米松与玻璃体内注射阿柏西普植入物治疗黄斑水肿的疗效和安全性：一项系统评价和荟萃分析
Eur J Med Res. 2025 Apr 15;30(1):273. doi: 10.1186/s40001-025-02404-x.
3
Natural remedies proposed for the management of diabetic retinopathy (DR): diabetic complications.用于治疗糖尿病视网膜病变（DR）的天然疗法：糖尿病并发症。
Naunyn Schmiedebergs Arch Pharmacol. 2025 Feb 15. doi: 10.1007/s00210-025-03866-w.
4
Innovator ranibizumab ComparEd to Biosimilar ranibizumab in combination with Expansile gas in submaculaR HemorrhaGe: the ICEBERG study.在黄斑下出血中，创新型雷珠单抗与生物类似药雷珠单抗联合膨胀性气体的比较：冰山研究
BMC Ophthalmol. 2025 Jan 23;25(1):41. doi: 10.1186/s12886-025-03846-x.
5
Efficacy & safety of brolucizumab 6.0 mg versus 3.6 mg in diabetic macular edema.6.0毫克与3.6毫克布罗卢izumab治疗糖尿病性黄斑水肿的疗效与安全性比较
Int J Retina Vitreous. 2025 Jan 13;11(1):6. doi: 10.1186/s40942-025-00628-x.
6
Multi-Omics Integration With Machine Learning Identified Early Diabetic Retinopathy, Diabetic Macula Edema and Anti-VEGF Treatment Response.机器学习辅助的多组学整合用于早期糖尿病视网膜病变、糖尿病性黄斑水肿及抗血管内皮生长因子治疗反应的识别
Transl Vis Sci Technol. 2024 Dec 2;13(12):23. doi: 10.1167/tvst.13.12.23.
7
The effect of diabetes on short-term outcomes following epiretinal membrane surgery.糖尿病对视网膜前膜手术后短期预后的影响。
Int Ophthalmol. 2024 Dec 5;44(1):446. doi: 10.1007/s10792-024-03373-6.
8
Potential Drug Targets for Diabetic Retinopathy Identified Through Mendelian Randomization Analysis.通过孟德尔随机化分析鉴定出的糖尿病性视网膜病变的潜在药物靶点。
Transl Vis Sci Technol. 2024 Nov 4;13(11):17. doi: 10.1167/tvst.13.11.17.
9
Is longer axial length protective of vision-threatening diabetic retinopathy across different ages? A multicenter cohort of 736 patients.在不同年龄段中，较长的眼轴长度对威胁视力的糖尿病视网膜病变有保护作用吗？一项针对736名患者的多中心队列研究。
Int J Retina Vitreous. 2024 Oct 10;10(1):74. doi: 10.1186/s40942-024-00593-x.
10
Recent advances in the treatment and delivery system of diabetic retinopathy.糖尿病视网膜病变的治疗和递药系统的最新进展。
Front Endocrinol (Lausanne). 2024 Feb 15;15:1347864. doi: 10.3389/fendo.2024.1347864. eCollection 2024.
本文引用的文献
1
Treatment Efficacy and Compliance in Patients with Diabetic Macular Edema Treated with Ranibizumab in a Real-Life Setting.雷珠单抗治疗糖尿病性黄斑水肿患者的实际疗效及依从性
J Ophthalmol. 2018 Apr 18;2018:4610129. doi: 10.1155/2018/4610129. eCollection 2018.
2
The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema.RESTORE 研究：雷珠单抗单药治疗或联合激光治疗与单纯激光治疗糖尿病黄斑水肿的比较。
Ophthalmology. 2011 Apr;118(4):615-25. doi: 10.1016/j.ophtha.2011.01.031.
Zotero 插件